InflaRx (IFRX) announced that it has received a written notice, dated September 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market informing the Company that it has regained compliance with Nasdaq’s minimum bid price requirement set forth under Nasdaq Listing Rule 5450(a)(1).
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- InflaRx: Buy Rating Based on Promising C5a/C5aR Strategy and Strong Financial Position
- InflaRx assumed with a Buy at H.C. Wainwright
- InflaRx’s Hold Rating Amid Trial Delays and Uncertain Clinical Data
- InflaRx Reports Significant Losses in H1 2025 Financials
- InflaRx reports Q2 EPS (21c) vs. (24c) last year